Literature DB >> 2859067

Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction.

T Kolakowska, A O Williams, M Ardern, M A Reveley, K Jambor, M G Gelder, B M Mandelbrote.   

Abstract

Seventy-seven patients with diagnosis of schizophrenia (62) or schizoaffective disorder (15) were studied 2-20 years since onset of illness, when in a stable condition. The investigation included clinical assessment, measurement of plasma concentrations of neuroleptics and prolactin, computed tomography brain scan, neuropsychological and neurological examination. Outcome of illness was classified according to the presence of chronic psychiatric symptoms and social impairment, and response to neuroleptics according to the effect of treatment in the most recent psychotic episode. Neither outcome nor response to neuroleptics was related to duration of illness. The groups with good and poor outcome differed in premorbid adjustment, age at onset and symptoms of the initial episode, but not in drug bio-availability or prolactin response. Large cerebral ventricles and cognitive impairment, but not neurological 'soft' signs, were associated with unfavourable outcome. The three measures of organicity were not inter-related. No clinical differences were found between chronic patients with and without signs of organic dysfunction. The findings suggest that schizophrenia with good and unfavourable outcome may be separate sub-types. However, the role of organic factors in the latter group remains unclear.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859067     DOI: 10.1192/bjp.146.3.229

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  29 in total

1.  Baseline serum prolactin in drug-naive, first-episode schizophrenia and outcome at five years: is it a predictive factor?

Authors:  Amresh Shrivastava; Megan Johnston; Yves Bureau; Nilesh Shah
Journal:  Innov Clin Neurosci       Date:  2012-04

Review 2.  Negative symptoms: psychopathological models.

Authors:  J Ananth; A Djenderdjian; P Shamasunder; J Costa; J Herrera; J Sramek
Journal:  J Psychiatry Neurosci       Date:  1991-03       Impact factor: 6.186

Review 3.  Very poor outcome schizophrenia: clinical and neuroimaging aspects.

Authors:  Serge A Mitelman; Monte S Buchsbaum
Journal:  Int Rev Psychiatry       Date:  2007-08

Review 4.  Adolescent schizophrenia: a methodologic review of the current neuroimaging and neuropsychologic literature.

Authors:  R L Findling; L Friedman; J T Kenny; T P Swales; D M Cola; S C Schulz
Journal:  J Autism Dev Disord       Date:  1995-12

5.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

6.  Tardive psychosis: does it exist?

Authors:  T Palmstierna; B Wistedt
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia.

Authors:  S Shaikh; D A Collier; P C Sham; D Ball; K Aitchison; H Vallada; I Smith; M Gill; R W Kerwin
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

8.  The relationship of structural brain imaging parameters to antipsychotic treatment response: a review.

Authors:  L Friedman; C Lys; S C Schulz
Journal:  J Psychiatry Neurosci       Date:  1992-06       Impact factor: 6.186

9.  A computed tomographic study of schizophrenia.

Authors:  N Lal; S C Tewari; P K Dalal; N Kohli; S Srivastava
Journal:  Indian J Psychiatry       Date:  1997-04       Impact factor: 1.759

10.  Plasma levels of fluphenazine and prolactin in psychiatric patients.

Authors:  T Kitamura; D A McGovern; N W Imlah; D Wiles; A A Schiff
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.